NCT06492759View on ClinicalTrials.gov

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

February 12, 2026

Study Completion Date

February 13, 2027

Conditions
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma
Interventions
RADIATION

Radiation Therapy

Undergo radiation therapy

BIOLOGICAL

Pembrolizumab

Given IV

DRUG

Nab-paclitaxel

Given IV

DRUG

Paclitaxel

Given IV

DRUG

Carboplatin

Given IV

DRUG

Gemcitabine

Given IV

PROCEDURE

Biopsy

Undergo biopsy

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Bone Scan

Undergo bone scan

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

OTHER

Medical Chart Review

Ancillary studies

Trial Locations (1)

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Emory University

OTHER